Live Glenmark Life Sciences Share Price Chart

O 885

H 885

L 885

VOL 108

Glenmark Life Sciences Performance

Days Range

Low: ₹873.30
High: ₹888.55
Previous Close ₹888.30
Open ₹885.00
Volume 87,530
Day’s Range ₹873.30 - ₹888.55
52W Range ₹370.00 - ₹906.00
Market Cap ₹10,889 Cr

Glenmark Life Sciences Fundamentals

ROCE (TTM) 74.19
P/E Ratio (TTM) 15.35
P/B Ratio 2.98
Industry P/E 36.55
Debt to Equity 0
ROE 46.71
EPS (TTM) 28.69
Dividend Yield 4.77
Book Value 147.95
Face Value 2

Glenmark Life Sciences Financials

Mar 2023Jun 2023Sep 2023Dec 2023
Net Sales621.32578.45595.36572.8
Expenses426.41397.9441.41413.43
Profit before tax197.63182158.93160.68
Operating Profit146.36135.45118.74118.77
Net Profit146.36135.45118.74118.77
EPS in Rs11.9411.059.699.69

About Glenmark Life Sciences

History of Glenmark Life Sciences Limited

Incorporated in 2011, Glenmark Life Sciences Limited is involved in the manufacturing of pharmaceuticals, chemicals and chemical products, medicinal chemicals and botanical products.

Glenmark Life Sciences Limited’s journey began in 2001 when Glenmark Pharmaceuticals set up its Active Pharmaceutical Ingredient (API) business. In 2002, they set up a manufacturing unit at Kurkumbh, Maharashtra. In the next year, the company’s first product was registered with the US FDA (Food and Drug Administration). In the same year, they acquired a manufacturing unit of Glaxo SmithKline’s (GSK) API in Ankleshwar, Gujarat. In 2004, they started manufacturing at Mohol, Maharashtra.

The company’s Ankleshwar manufacturing unit was inspected by the US FDA in 2008, then by PMDA (Pharmaceuticals and Medical Devices Agency) and AFSSAPS (Agence française de sécurité sanitaire des. produits de santé), France in 2012 and by COFEPRIS (Mexico Ministry of Health) in 2013. In the same year, i.e., 2013, the company’s manufacturing unit at Dahej, Gujarat, started its operations, and it was inspected by the US FDA in 2015.

In 2019, the company’s API business was separated into Glenmark Life Sciences. In 2021, the company reached a milestone of 403 cumulative Drug Master Files (DMFs) across multiple markets worldwide. In the same year, Glenmark Life Sciences went public and got listed on the stock exchanges in India.

As of March 2023, Glenmark Life Sciences has an API portfolio of 139 molecules and caters to customers across more than 75 countries in the world, including Japan, North America, Europe, Latin America and more. They have 4 plants, where 2 are in Maharashtra, 2 are in Gujarat and 1 R&D site at Navi Mumbai. Their API plants are regularly inspected by prominent global authorities such as PMDA, the US FDA and other regulatory agencies in Europe, Canada, Russia and Korea.

Business Segments of Glenmark Life Sciences Limited 

The business solutions and services offered by the company are as follows:

  • API: This is the primary business segment of the company. Under this, the company manufactures and supplies APIs to pharmaceutical companies globally. The company’s product portfolio contains 137 APIs across various therapeutic segments, such as Cardiovascular, Central Nervous System disorders, Diabetes, Gastrointestinal health, Oncology, Pain management, and Anti-Infectives.
  • End-to-end support: In this segment, the company offers support to their partners right from product development to analytical development and support and API and Intermediate manufacturing.

As of March 31, 2023, there are no subsidiaries of Glenmark Life Sciences Limited.

Key Personalities of Glenmark Life Sciences Limited

Dr Yasir Rawjee, Managing Director and Chief Executive Officer

Dr Yasir Rawjee is the Managing Director and Chief Executive Officer of Glenmark Life Sciences Limited. He steers the overall operations and business strategy of the company. He holds more than 20 years of experience in the pharmaceutical industry. Before joining Glenmark Life Sciences Limited, he worked at GlaxoSmithKline in the USA, at Mylan Laboratories Limited as the head of global API operations, and also as the Senior Vice President at Matrix Laboratories Limited.

Parent Organisation Indian Private
Founded 2011
Managing Director Glenn Saldanha
NSE Symbol GLS

Peer Comparison

Stocks Market Cap (cr) Market Price (₹) 52 Week Low-High (₹)
Supriya Lifescience Ltd ₹2,884.91

341.1

17.00 (-4.75%)

336.85 - 361.65
Celestial Biolabs Ltd ₹4.56

1.75

0.00 (0.00)

1.75 - 1.8
JFL Life Sciences Ltd ₹49.77

45.6

0.35 (0.77%)

45.6 - 47
Procter & Gamble Health Ltd ₹8,453.38

5089.25

8.85 (0.17%)

5050 - 5110.5
Veerhealth Care Ltd ₹47.34

26

0.00 (0.00)

26 - 26

What's Trending

Glenmark Life Sciences FAQs

What is the Share price of Glenmark Life Sciences (GLS)?

Glenmark Life Sciences (GLS) share price as of February 28, 2024, on NSE is Rs 876.80 (NSE) and Rs 876.90 (BSE) on BSE.

Can I buy Glenmark Life Sciences (GLS) shares?

Yes, You can buy Glenmark Life Sciences (GLS) shares by opening a Demat account with Angel One.

How do I buy Glenmark Life Sciences (GLS) from Angel One?

Glenmark Life Sciences (GLS) share can be brought through the following modes:
  1. Direct investment: You can buy Glenmark Life Sciences (GLS) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Glenmark Life Sciences (GLS) shares.

Is Glenmark Life Sciences a Debt free Company?

Glenmark Life Sciences is almost a debt-free company. Its debt-to-equity ratio is very low.

What is the main business of Glenmark Life Sciences?

The main business of Glenmark Life Sciences is manufacturing and selling high-quality Active Pharmaceutical Ingredients (APIs) to pharmaceutical companies across the globe. The company produces a range of APIs for various therapeutic categories, including the cardiovascular, central nervous system, anti-diabetic, and respiratory.

What are the Subsidiaries that comes under Glenmark Life Sciences?

Glenmark Life Sciences does not have any subsidiaries. However, Glenmark Pharmaceuticals, the parent company, has several subsidiaries.